Formula I [wherein one of R 1, the present invention is hydrogen, halogen, aryl, heterocyclyl, heteroaryl, cyano, lower alkyl, - (CH 2) n - cycloalkyl, - (CH 2) n -N (R ) 2, or - (CH 2) n -O--lower alkyl - be a (CH 2) n -OH are R, is hydrogen or lower alkyl or 2 is 0,1 n, R 2 is , optionally, heterocyclyl cycloalkyl, aryl, heteroaryl or aryl (these are halogen lower alkyl which is substituted by halogen lower alkoxy substituted by halogen, cyano, nitro lower alkyl lower alkoxy C (O The optionally substituted hydroxy, lower alkyl or halogen optionally benzyloxy -) O- lower alkyl lower alkylsulfonyl -NR a R b -C (O) -NR a R b heterocyclyl -C (O) is an heteroaryl substituted by lower alkyl, or, optionally, a) are substituted with one or more members selected from the group consisting of heterocyclyl are R b and R a is, independently, hydrogen, lower alkyl sulfonyl, -C (O) H, - (CH 2) n -N (R) 2, - (CH 2) n -O--lower alkyl, - (CH 2) n -S- lower alkyl, - is substituted by lower alkyl lower alkyl, heteroaryl-sulfonyl, lower alkyl, optionally the - - (CH 2) n -S (O) 2 or heterocyclyl, or - - (CH 2) n (CH 2) (wherein, R is is lower alkyl, heteroaryl, or cycloalkyl (CO) -R - n - cycloalkyl, - (CH 2) n - heteroaryl, - (CH 2) n -OH, present) shown (these in] a) is substituted by lower alkyl halogen, or is substituted by halogen, optionally aryl or heteroaryl, R 3 is isoxazol-4-yl - Okisaji relates to acid addition salts pharmaceutically acceptable as well as azole derivatives. This class of compounds, that the nootropic drugs useful for the treatment of cognitive disorders or such as Alzheimers disease and showed selectivity and high affinity for GABA A α5 receptor binding sites found have.本発明は、式I[式中、R1は、水素、ハロゲン、アリール、ヘテロシクリル、ヘテロアリール、シアノ、低級アルキル、-(CH2)n-シクロアルキル、-(CH2)n-N(R)2、-(CH2)n-O-低級アルキル又は-(CH2)n-OHであり;nは、0、1又は2であり;Rは、水素又は低級アルキルであり;R2は、シクロアルキル、アリール、ヘテロアリール又はヘテロシクリル(これらは、場合により、ハロゲン;シアノ;ニトロ;低級アルキル;低級アルコキシ;ハロゲンで置換されている低級アルコキシ;ハロゲンで置換されている低級アルキル;C(O)O-低級アルキル;低級アルキルスルホニル;-NRaRb;-
